Olumiant: Withdrawal of the application to change the marketing authorisation
baricitinib
Table of contents
Overview
Eli Lilly Nederland B.V. withdrew its application for the use of Olumiant in the treatment of patients hospitalised with COVID-19.
The company withdrew the application on 7 December 2022.
Key facts
Name |
Olumiant |
Product number |
EMEA/H/C/004085 |
Date of issue of market authorisation valid throughout the European Union (if applicable) |
13/02/2017 |
International non-proprietary name (INN) or common name |
|
Active substance |
|
Date of withdrawal |
07/12/2022 |
Company making the application | |
Withdrawal type |
Post-authorisation |
All documents
-
List item
Withdrawal assessment report for Olumiant (II-0028) (PDF/5.8 MB)
Adopted
First published: 02/02/2023
EMA/926734/2022 -
List item
Withdrawal letter : Olumiant (II-0028) (PDF/9.41 KB)
First published: 16/12/2022 -
List item
Questions and answers on the withdrawal of application to change the marketing authorisation for Olumiant (baricitinib) (PDF/130.83 KB)
First published: 16/12/2022
Last updated: 02/02/2023
EMA/931846/2022 -
Related information on withdrawals
This text will be replaced by the description of taxonomy term "Template for related information on withdrawals" from vocabulary "String replacement".